<DOC>
	<DOC>NCT02115204</DOC>
	<brief_summary>Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer (BC). The magnitude of benefit in intermediate-risk N+ early BC is still unclear. West German Study Group and "Arbeitsgemeinschaft Gyn√§kologische Onkologie" (WSG-AGO) EC-Doc is a large trial evaluating modern sequential taxane-based chemotherapy in the subgroup with 1-3 involved lymph nodes (LN).</brief_summary>
	<brief_title>4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Female patients Age 1865 years Eastern Cooperative Oncology Group (ECOG) status &lt; 2 Surgery: R0resection and &gt;= 10 removed axillary lymph nodes M0 by chest xray, bone scintigraphy and liver sonography Polyneuropathy Creatinin (serum) &gt; 1,4 mg/dl; Bilirubin (serum) &gt; 2,0 mg/dl Cardia dysfunction, ejection fraction &lt; lower normal value of each institution Hematopoeitic insufficiency: leucocytes &lt; 3,5 G/l, thrombocytes &lt; 100 G/l second malignant neoplasia, except curatively treated basalioma of the skin Surgery before more the six weeks (42 days) Concurrent pregnancy; patients of childbearing potential must implement a highly effective (less than 1% failure rate) nonhormonal contraceptive measures during the study treatment Breast feeding woman Sequential breast cancer Reasons indicating risk of poor compliance Patients not able to consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>